MedTrace Logo

Eletriptan Pharmacokinetics In Korean Males

NCT01139515 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.

Conditions

  • Healthy

Interventions

DRUG

Eletriptan commercial tablet

20 mg tablet, single dose

DRUG

Eletriptan commercial tablet

40 mg tablet, single dose of 1 X 40 mg

DRUG

Eletriptan commercial tablet

40 mg tablet, single dose of 2 X 40 mg

DRUG

Eletriptan commercial tablet

40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139515 on ClinicalTrials.gov